MedTrace Logo

Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.

NCT05163405 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2025-08-22

No results posted yet for this study

Summary

In the present study, we have trained 10 patients in subcutaneous self-administration of Velcade. After their training, patients will alternately receive their treatment in the hospital and at home by self-administration. In keeping with common practice, a nurse contacts the patients by telephone before 9.00 am on the day of treatment to ensure that the patient is physically "fit" to receive the medication and to discuss any side effects. To highlight the advantages and disadvantages of the changed treatment practice from the perspectives of both patients and healthcare professionals, data is collected from two consecutive semi-structured interviews with n = 10 patients and n = 1 focus group interview of the healthcare professionals involved. Moreover, time registration of medication administration both at the hospital and in the patients' home is done. The qualitative data will be analyzed via the method of condensation and continual quantitative data will form the basis of a cost-benefit analysis.

Conditions

Interventions

DRUG

Bortezomib

Self-administration of subcutaneously Velcade.

Sponsors & Collaborators

  • Karin B. Ø. Dieperink

    lead OTHER

Principal Investigators

  • Karin Brochstedt Dieperink, RN · Odense University Hospital. Department of Oncology.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2022-01-01
Completion
2022-06-01
FDA Drug
Yes

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05163405 on ClinicalTrials.gov